Aspen Investment Management Inc Has $786,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Aspen Investment Management Inc decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,611 shares of the medical research company’s stock after selling 265 shares during the quarter. Aspen Investment Management Inc’s holdings in Edwards Lifesciences were worth $786,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Concurrent Investment Advisors LLC grew its holdings in Edwards Lifesciences by 2.3% in the 4th quarter. Concurrent Investment Advisors LLC now owns 19,626 shares of the medical research company’s stock valued at $1,453,000 after buying an additional 439 shares in the last quarter. Abacus Planning Group Inc. raised its holdings in Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after acquiring an additional 140 shares in the last quarter. Private Advisor Group LLC grew its holdings in shares of Edwards Lifesciences by 79.4% during the 4th quarter. Private Advisor Group LLC now owns 21,326 shares of the medical research company’s stock worth $1,579,000 after purchasing an additional 9,440 shares in the last quarter. Pegasus Asset Management Inc. raised its stake in Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after purchasing an additional 159 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its stake in Edwards Lifesciences by 1,013.3% during the fourth quarter. Venturi Wealth Management LLC now owns 2,683 shares of the medical research company’s stock worth $199,000 after buying an additional 2,442 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,489 shares of company stock valued at $2,002,829. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on EW. Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $74.71 on Friday. The company has a market cap of $44.06 billion, a P/E ratio of 10.72, a PEG ratio of 4.89 and a beta of 1.10. The business has a 50-day moving average price of $72.86 and a two-hundred day moving average price of $69.86. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.